Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic

Hirokuni Akahori1, Takeshi Tsujino, Yoshiro Naito

  • 1aCardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya bDepartment of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan.

Insights

Atorvastatin improved diastolic heart function and reduced cardiac fibrosis in rats with hypertension. This effect is linked to decreased heat shock protein 47 (HSP47) via the Rho-Rho kinase pathway.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Diastolic heart failure is a growing concern, with statins showing potential benefits.
  • The precise mechanisms underlying statin efficacy in diastolic heart failure remain unclear.
  • Dahl salt-sensitive rats serve as a relevant model for studying hypertensive diastolic heart failure.

Purpose of the Study:

  • To investigate the effects of atorvastatin on cardiac function in a rat model of hypertensive diastolic heart failure.
  • To elucidate the molecular mechanisms by which atorvastatin exerts its beneficial effects on cardiac fibrosis and diastolic function.

Main Methods:

  • Dahl salt-sensitive rats were assigned to low-salt, high-salt, or high-salt + atorvastatin groups.
  • Cardiac structure and function were assessed using echocardiography and histology.
  • Expression of fibrosis-related molecules, including heat shock protein 47 (HSP47), was examined in cardiac tissue and fibroblasts.

Main Results:

  • High salt intake induced left ventricular hypertrophy, diastolic dysfunction, and cardiac fibrosis.
  • Atorvastatin treatment improved diastolic function and reduced cardiac fibrosis without affecting blood pressure.
  • Atorvastatin decreased HSP47 expression, an effect mediated by the Rho-Rho kinase pathway.

Conclusions:

  • Atorvastatin ameliorates cardiac fibrosis and diastolic dysfunction in a rat model of hypertensive heart failure.
  • Reduced HSP47 expression via Rho-Rho kinase pathway inhibition is a key mechanism for atorvastatin's beneficial effects.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626